Using chitosan-stabilized, hyaluronic acid-modified selenium nanoparticles to deliver CD44-targeted PLK1 siRNAs for treating bladder cancer Supplementary data

Aims: Achieving an effective biocompatible system for siRNAs delivery to the tumor site remains a

significant challenge. Materials & methods: Selenium nanoparticles (SeNPs) modified by chitosan (CS) and

hyaluronic acid (HA) were fabricated for PLK1 siRNAs (siPLK1) delivery to the bladder cancer cells. The

HA-CS-SeNP@siPLK1 efficacy was evaluated using in vitro and in vivo models. Results: HA-CS-SeNP@siPLK1

was selectively internalized into T24 cells through clathrin-mediated endocytosis. Treatment with HA-CSSeNP@

siPLK1 successfully silenced the PLK1 gene, inhibited cell proliferation and induced cell cycle arrest

in vitro. HA-CS-SeNP@siPLK1 could also inhibit tumor growth in vivo without causing systemic toxicity.

Conclusion: Our results suggest that HA-CS-SeNPs may provide a good vehicle for delivering siPLK1 to the

bladder tumor site.